ICER releases evidence reports on therapies for ulcerative colitis and haemophilia A Unknown 31 October 2020 Pages: 1 - 1
Access to newly funded T2DM drugs would benefit patients most in need in New Zealand Clinical study 31 October 2020 Pages: 3 - 3
Assessing indirect cost burden of employed MS patients on DMT in US Clinical study 31 October 2020 Pages: 4 - 4
Barriers to care for underinsured patients at high-volume hospitals Clinical study 31 October 2020 Pages: 5 - 5
Claims payments reduced after biosimilar filgrastim launched in US Clinical study 31 October 2020 Pages: 6 - 6
Counting the costs of immunisation in Tanzania to inform policy decisions Non-clinical study 31 October 2020 Pages: 8 - 8
Dalbavancin vs SOC for acute bacterial skin and skin structure infections Clinical study 31 October 2020 Pages: 9 - 9
Decision rule-based strategy saves cost in children with suspected LRTI Clinical study 31 October 2020 Pages: 10 - 10
Delayed generic entry for buprenorphine large effect on Medicaid spend Non-clinical study 31 October 2020 Pages: 11 - 11
Early, effective response to COVID-19 will reduce large resource needs Epidemiology population study 31 October 2020 Pages: 12 - 12
Economic evaluations of interventions for opioid overdose and abuse Clinical study 31 October 2020 Pages: 14 - 14
Examining country-level decisions on introducing HPV vaccine 2006−2018 Non-clinical study 31 October 2020 Pages: 15 - 15
HBV/HCV testing/treatment scale-up across WHO regions cost effective Clinical study 31 October 2020 Pages: 17 - 17
HCV screening and treatment among pregnant women cost effective Clinical study 31 October 2020 Pages: 18 - 18
Higher financial benefit of ACA in lower income families Clinical study 31 October 2020 Pages: 19 - 19
Immunisation programmes generate significant global economic benefits Epidemiology population study 31 October 2020 Pages: 20 - 20
Insights into UK NICE diagnostic-technology assessment decisions Non-clinical study 31 October 2020 Pages: 21 - 21
Intervention for low-level drug offenders: large benefits, acceptable cost Clinical study 31 October 2020 Pages: 22 - 22
Linked HIV/SARS-CoV-2 testing could reduce incidence of HIV and costs Clinical study 31 October 2020 Pages: 23 - 23
Osimertinib cost effective in EGFR T790-mutated NSCLC in China Clinical study 31 October 2020 Pages: 24 - 24
Pembrolizumab in head and neck cancer cost effective in US, not in China Clinical study 31 October 2020 Pages: 25 - 25
Population health outcomes hindered by autocratisation Non-clinical study 31 October 2020 Pages: 26 - 26
Pulmonary rehabilitation for COPD: improves outcomes at acceptable cost Review 31 October 2020 Pages: 27 - 27
Shortage of economic evaluations in cancer treatment trials in the US Review 31 October 2020 Pages: 28 - 28
Substantial health and economic burden of migraine in Australia Clinical study 31 October 2020 Pages: 29 - 29
The PACTS principles for patient involvement in health economics research Non-clinical study 31 October 2020 Pages: 31 - 31
Transplantation the most cost-effective kidney replacement therapy Review 31 October 2020 Pages: 32 - 32
Updated estimate of the cost effectiveness of riluzole for ALS in the US Clinical study 31 October 2020 Pages: 33 - 33
US Ryan White HIV/AIDS Program: cost-effective use of public resources Clinical study 31 October 2020 Pages: 34 - 34
Draft guidance from NICE recommends siponimod for secondary progressive MS News item 31 October 2020 Pages: 36 - 36